Regeneron falls on forecast for 50% hike in Eylea sales; Pfizer wins EU nod for new Prevenar use;

@FiercePharma: Allergan eager to offload its obesity business (Lap-Band, etc) this quarter. PrivateEquity in on the hunt, CEO says. More | Follow @FiercePharma

@EricPFierce: Warburg Pincus' $195 million deal for JHP says something about the market for sterile injectable drugs. Story | Follow @EricPFierce

 @AlisonBFierce:  Rates of HPV-related cancers remain stubbornly high in the United States. More | Follow @AlisonBFierce

> A victim of its own success, Regeneron ($REGN) disappointed investors with predictions of 50% increases in sales of its Eylea drug for 2013, after reaching $838 million in 2012. Report

> Aiming to reach $2 billion in revenue, Cubist Pharmaceuticals ($CBST) will need to make its largest acquisition ever, because its pipeline isn't sufficient enough to boost sales to that level, analysts said. Report

> Pfizer ($PFE) nabbed a new European approval for its Prevenar 13 vaccine as a preventive for kids 6 to 17 years of age. Release | Report

> Allergan ($AGN) is eager to offload its obesity business by the end of the first quarter, CEO David Pyott said. Report

> Endo Health Solutions ($ENDP) and Pfizer each are paying $18.17 million to the state of Texas to settle allegations of Medicaid fraud. Report

> Novartis ($NVS) and Eisai have called it quits on their co-promotion agreement for three of Novartis' treatments for chronic obstructive pulmonary disease. Report

> Savient Pharmaceuticals ($SVNT) added Genzyme CEO David Meeker to its board of directors. Report

Medical Device News

 @FierceMedDev: JPM: T2 readies pivotal trial for Candida assay. Story | Follow @FierceMedDev

@MarkHFierce: A new NC startup wants to grow replacement corneas from donor cells and scaffolding. Story | Follow @MarkHFierce

 @DamianFierce: Fierce 15'er CardioKinetix is kicking off a pivotal trial for its heart-failure tech. Article | Follow @DamianFierce

> JPM: For med tech startups, fundraising hinges on establishing value. Report

> JPM: Medtronic's Ishrak promises more M&A, globalization. News

Biotech News

 @FierceBiotech: From India's vaccine prices soar as private companies gain ground. Story | Follow @FierceBiotech

@JohnCFierce: Sanofi's case for R&D turnaround includes a few setbacks for cancer, MS - coming up at JPM13 pipeline review. News | Follow @JohnCFierce

@RyanMFierce: Third Rock selling a preclinical stage portfolio company is interesting. It's TRV's 2nd exit, and they're gonna need wins to raise more $$. | Follow @RyanMFierce

> Boehringer tosses back rights to one of Lilly's key PhIII diabetes programs. News

> Bob Langer biotech lands first big biopharma deal with Amgen. Story

> Shire gambles on one-man biotech startup to gain ultra-orphan drug. Report

Pharma Manufacturing News

> Novartis finds blister packs sell more drugs. Story

> Lonza doubling ADC capacity at Visp. Report

> Malaysia's location, domestic market draw Ranbaxy, Cipla, others. Article

> Exela investing in North Carolina plant. News

Biotech Research News

> Mouse results unlock metformin's secrets. Story

> Addex preclinical drug slows inherited neuropathy. News

> Using gene therapy to fix a scarred heart. Report

> Cell transplant gives blind mice their sight back. Item

And Finally... A large new study found no links between antidepressants and stillbirths. Report

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.